Ehab L. Atallah, MD

Articles

Closing Thoughts on the MDS Treatment Landscape

March 26th 2024

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Takeaways from ASH 2023 in Higher-Risk MDS

March 19th 2024

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

Updates from ASH 2023 in Higher-Risk MDS

March 19th 2024

Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.

Treatment Options and Unmet Needs in Higher-Risk MDS

March 12th 2024

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

March 12th 2024

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

March 5th 2024

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

IMerge: Imetelstat in Patients With Lower-Risk MDS

March 5th 2024

The expert panel discusses abstracts surrounding the IMerge clinical trial on imetelstat in patients with lower-risk myelodysplastic syndromes.

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

February 27th 2024

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

February 27th 2024

Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.

ESA Treatment Selection in MDS

February 20th 2024

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

February 20th 2024

Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.

Patient Profile 2: A 77-Year-Old Man With MDS

February 14th 2024

The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.

Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

February 14th 2024

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

Patient Profile 1: A 72-Year-Old Man With MDS

February 6th 2024

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

February 6th 2024

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Risk Stratification of Myelodysplastic Syndromes

January 30th 2024

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

Diagnosis of Myelodysplastic Syndromes (MDS)

January 30th 2024

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

Dr. Atallah on the Prognostic Role of Undetectable MRD in CLL

August 31st 2021

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.